Sung RJ et al. Mechanisms of spontaneous alternation between reciprocating tachycardia and atrial

flutter/fibrillation in the Wolff-Parkinson-White syndrome. Circulation. 1977;56:409.

Tijunelis MA et al. Myth: intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-ParkinsonWhite syndrome in the emergency department. CJEM. 2005;7:262–265.

Gulamhusein S et al. Acceleration of the ventricular response during atrial fibrillation in the Wolff-ParkinsonWhite syndrome after verapamil. Circulation. 1982;65:348.

Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter [published correction appears in Ann

Intern Med. 1992;117:446]. Ann Intern Med. 1992;117:141.

Aliot E et al. Twenty-five years in the making: flecainide is safe and effective for the management of atrial

fibrillation. Europace. 2010;13:161–173.

Krahn AD et al. A randomized, double-blind, placebo controlled evaluation of the efficacy and safety of

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

123.

124.

125.

intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome. Pacing Clin

Electrophysiol. 2008;24:1258–1260.

Cohen MI et al. PACES/HRS expert consensus statement on the management of the asymptomatic young

patient with a Wolff-Parkinson-White (WPW, Ventricular Preexcitation) Electrocardiographic pattern. Heart

Rhythm. 2012;9:1006–1024

Barra SN et al. A review on advanced atrioventricular block in young or middle-aged adults. Pacing Clin

Electrophysiol. 2012;35:1395–1405.

Pedersen CT et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Heart Rhythm.

2014;11:e166–e196.

Majorowicz K. Clinical Management of Ventricular Arrhythmias. Sacramento, CA: CME Resource; 2008.

Cantillon DJ et al. Evaluation and management of premature ventricular complexes. Cleve Clin J Med.

2013;80:377–387.

Echt DS et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac

Arrhythmia Suppression Trial. N EnglJ Med. 1991;324:781.

[No authors listed]. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The

Cardiac Arrhythmia Suppression Trial II Investigators. N EnglJ Med. 1992;327:227.

Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the

postinfarction period. Am J Cardiol. 1997;80(9B):35J.

Freemantle N et al. Beta-blockade after myocardial infarction: systematic review and meta regression analysis.

BMJ. 1999;318:1730.

Kendall MJ et al. Beta-blockers and sudden cardiac death. Ann Intern Med. 1995;123:358.

[No authors listed]. Randomised trial of intravenous atenolol among 16, 027 cases of suspected acute myocardial

infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet. 1986;2:57.

Chen ZM et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction:

randomised placebo-controlled trial. Lancet. 2005;366:1622.

O’Gara PT et al. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction: a

report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice

Guidelines. J Am Coll Cardiol. 2013;61:e79–e140.

Caims JA et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive

ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial

Investigators [published correction appears in Lancet. 1997;349: 1776]. Lancet. 1997;349:675.

Julian DG et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular

dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarction Amiodarone Trial

Investigators [published corrections appear in Lancet. 1997;349:1776; Lancet. 1997;349:1180]. Lancet.

1997;349:667.

Buxton AE et al. Nonsustained ventricular tachycardia in coronary artery disease: relation to inducible sustained

ventricular tachycardia. MUSTT Investigators. Ann Intern Med. 1996;125:35.

Connolly SJ. Meta-analysis of antiarrhythmic drug trials. Am J Cardiol. 1999;84:90R–93RR.

Farre J et al. Amiodarone and “primary” prevention of sudden death: critical review of a decade of clinical trials.

 

175

showed significantly lower rates of 1-month survival and 1-month survival with

favorable neurologic outcomes in out-of-hospital cardiac arrest patients with

shockable rhythm, who received epinephrine before hospital arrival, relative to

patients who did not receive epinephrine (p < 0.001).

On the basis of these trials, it would be reasonable to use a single dose of

vasopressin 40 units as an alternative to either the first or second dose of epinephrine

1 mg in the treatment of VF (or pulseless VT).

CASE 15-9, QUESTION 3: One of the physicians delivering ACLS for M.N. wants to initiate corticosteroid

therapy. What is the evidence supporting the use of corticosteroid therapy in patients experiencing cardiac

arrest?

A randomized, double-blind, placebo-controlled, parallel-group trial performed

by Mentzelopoulos et al.

176 assessed the impact of using two different strategies for

managing in-hospital cardiac arrest patients on: (a) survival to hospital discharge

with favorable neurologic status; and (b) probability for return of spontaneous

circulation for 20 minutes or longer. One group of patients received epinephrine (1

mg/CPR cycle), vasopressin (20 IU/CPR cycle), and corticosteroid therapy

(methylprednisolone 40 mg during first CPR cycle, then hydrocortisone 300 mg/day

[for post-resuscitation shock] for up to 7 days, followed by taper). The control group

received epinephrine in combination with saline placebo. Epinephrine–vasopressin–

corticosteroid recipients exhibited superior rates of probability for return of

spontaneous circulation for ≥20 minutes (83.9% vs. 65.9%; OR, 2.98; 95% CI, 1.39–

6.40; p = 0.005), and survival to hospital discharge with favorable neurologic status

(13.9% vs. 5.1%; OR, 3.28; 95% CI, 1.17–9.20; p = 0.02), compared to the control

group.

CASE 15-9, QUESTION 4: Because M.N. has an IV site and the time from cardiac arrest to ACLS was

brief, epinephrine was chosen and a 1-mg bolus was given, followed with a 20-mL normal saline flush. The arm

was elevated for 20 seconds to ensure adequate delivery. Thirty seconds after administration a 200-J shock is

given (via biphasic manual defibrillator), but it fails to convert VF. What can be done now?

The most recently updated ACLS guideline calls for the use of amiodarone in

cases of VF or pulseless VT that do not respond to CPR, shocks, and a

vasopressor.

167

IV AMIODARONE AND LIDOCAINE

The effect of amiodarone on VF or pulseless VT was studied in the ARREST

(Amiodarone for Resuscitation of Refractory Sustained Ventricular

Tachyarrhythmias) trial.

171 This study was conducted in patients who experienced

cardiac arrest in an out-of-hospital situation with therapy given by paramedics in the

field. Patients who failed three stacked shocks and one dose of epinephrine with an

electrical countershock were randomly assigned to amiodarone 300 mg IV bolus or

placebo. This was followed by other antiarrhythmic agents historically used in ACLS

(2,000 guidelines: lidocaine, procainamide, or bretylium) if the clinicians desired.

Amiodarone significantly increased the chance of survival to hospital admission

(44% vs. 34% of placebo group; p = 0.03), but survival to hospital discharge was

not changed. Of note, 66% of patients received antiarrhythmic drug treatment for

pulseless VT or VF after amiodarone administration.

The ALIVE (Amiodarone vs. Lidocaine in Ventricular Ectopy, n = 347) trial

directly compared IV amiodarone 300 mg to lidocaine 1 to 1.5 mg/kg bolus.

173

In this

trial, patients needed to fail three stacked shocks and epinephrine plus an additional

shock to be eligible for randomization to either amiodarone or lidocaine.

Amiodarone was given as an initial dose of 5 mg/kg followed by a shock. If

unsuccessful, a dose of 2.5 mg/kg was given followed by a subsequent shock.

Lidocaine was given as a 1.5 mg/kg bolus followed by a shock. If therapy failed, then

a second bolus of 1.5 mg/kg was used with a subsequent shock. If the first

antiarrhythmic drug failed, other routine antiarrhythmic drugs for cardiac arrest (per

2000 ACLS guidelines: e.g., procainamide, bretylium) could be tried. Patients given

amiodarone were 90% more likely to experience the primary outcome, survival to

hospital admission, than those given lidocaine (p = 0.009). Unfortunately, no

significant advantage to hospital discharge occurred (5% vs. 3%).

On the basis of these findings, amiodarone is the only antiarrhythmic agent with

proven ability to improve return of spontaneous circulation and short-term survival

versus other antiarrhythmic therapy. However, it has not yet been shown to improve

survival to hospital discharge.

M.N. is at serious risk of death as a result of VF. However, as long as M.N.

remains in VF, it is appropriate to continue active therapy. If M.N. degenerates into

asystole after this long period of VF, then the resuscitation efforts should be

discontinued. However, if a patient only had a brief period of VF before having

asystole, it is prudent to apply active therapy.

Pulseless Electrical Activity

CASE 15-10

QUESTION 1: J.D. is an 80-year-old woman who experiences cardiac arrest in the hospital. J.D. was in

respiratory failure upon admission to the ED, where she underwent immediate intubation, had a peripheral IV

placed, and upon transfer to the MICU, placed on assist/control mechanical ventilation with FiO2

of 100%. A

rhythm is noted on the monitor, but no femoral pulse is felt. M.N. is in PEA. How should J.D. be treated?

The clinical situation in which there is organized electrical activity on the monitor

without a palpable pulse is called PEA. Although electrical activity is present, it

fails to stimulate the contractile process. Virtually all patients in true PEA die.

However, not all patients who present with a rhythm and no pulse are in true PEA.

Therefore, it is important to rule out treatable causes in patients who appear to be in

PEA. The major treatable causes are hypovolemia, hypoxia, acidosis, hyperkalemia,

hypokalemia, hypothermia, cardiac tamponade, pulmonary embolism, acute coronary

syndrome, trauma, and drug overdose. In the absence of an identifiable cause, the

focus of resuscitation is to administer high-quality CPR, and after the initial rhythm

check, resume CPR during the establishment of IV or IO (intraosseous) access.

167

p. 331

p. 332

Figure 15-15 Asystole. There is no electrical activity detected in the heart resulting in a very low amplitude

undulating waveform.

Once IV or IO access becomes available, administer epinephrine 1 mg every 3 to

5 minutes or give one dose of vasopressin 40 units in place of the first or second

dose of epinephrine, as published studies have failed to demonstrate a survival

advantage of either vasopressor for patients experiencing PEA.

167,169,170

Asystole

CASE 15-11

QUESTION 1: K.K., a 73-year-old man, has a past medical history significant for hypertension and

diverticulitis. Upon arrival at the OR for surgical correction of pericardial and pleural effusions, K.K. received

etomidate, fentanyl, lidocaine, and succinylcholine. During placement of a double-lumen endotracheal tube, K.K.

goes into cardiac arrest. The ECG shows a flat line, and the patient is determined to be in asystole (Fig. 15-15).

Is this rhythm treatable?

Lack of electrical activity or asystole, like PEA, carries a grave prognosis. Its

development usually indicates a prolonged arrest, which may explain its poor

response to treatment. However, a few patients will go directly from a sinus rhythm

into asystole and may be resuscitated. Enhanced parasympathetic tone, possibly

attributable to a vagal reaction, manipulation of the airway from intubation,

suctioning or insertion of an oral airway, or chest compression, may play a role in

inhibiting supraventricular and ventricular pacemakers.

168

A post hoc analysis performed by Wenzel et al.

168 demonstrated superior survival

rates at the time of hospital admission in vasopressin-treated patients, compared with

epinephrine-treated patients. However, no difference in intact neurologic survival

was noted between the two treatment groups. Consequently, providers may choose to

administer vasopressin 40 units IV (in place of the first or second dose of

epinephrine) or epinephrine 1 mg IV every 3 to 5 minutes.

CASE 15-11, QUESTION 2: Does the timing of epinephrine dosing impact survival to hospital discharge in

patients with non-shockable rhythms (asystole or PEA)?

A post hoc analysis of data from the Get With the Guidelines-Resuscitation study

showed a stepwise reduction in survival to hospital discharge (primary study end

point) with each 3-minute delay to epinephrine: (a) 1 to 3 minutes (OR 1.0, reference

group); (b) 4 to 6 minutes (OR, 0.91; 95% CI, 0.82–1.00; p = 0.055); (c) 7 to 9

minutes (OR, 0.74; 95% CI, 0.63–0.88; p < 0.001); and (d) >9 minutes (OR, 0.63;

95% CI, 0.52–0.76; p < 0.001).

177

CASE 15-11, QUESTION 3: What is the long-term prognosis for patients with non-shockable rhythms?

Goto et al.

175 assessed the impact of pre-hospital epinephrine administration on

long-term outcomes seen in out-of-hospital cardiac arrest patients with nonshockable rhythms.

176 Epinephrine recipients showed superior 1-month survival rates

compared to patients who did not receive pre-hospital epinephrine (3.9% vs. 2.2%;

p < 0.001). However, pre-hospital administration of epinephrine did not result in

improved 1-month favorable neurologic outcomes (p = 0.62).

KEY REFERENCES AND WEBSITES

A full list of references for this chapter can be found at

http://thepoint.lww.com/AT11e. Below are the key references and websites for this

chapter, with the corresponding reference number in this chapter found in parentheses

after the reference.

Key References

Cohen MIet al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient

with a Wolff-Parkinson-White (WPW, Ventricular Preexcitation) Electrocardiographic pattern. Heart Rhythm.

2012;9:1006. (101)

Drew BJ et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American

Heart Association and the American College of Cardiology Foundation [published correction appears in

Circulation. 2010;122:e440]. Circulation. 2010;121:1047. (147)

Epstein AE et al. 2012 ACC/AHA/HRS focused update incorporated into the 2008 Guidelines for Device-Based

Therapy of Cardiac Rhythm Abnormalities. J Am Coll Cardiol. 2013;61:e6. (130)

Giugliano RP et al. Edoxaban versus warfarin in patients with atrial fibrillation. N EnglJ Med. 2013;369:2093. (84)

Granger CB et al. Apixaban versus warfarin in patients with atrial fibrillation. N EnglJ Med. 2011;365:981. (83)

Hazinski MF, ed. Highlights of the 2010 American Heart Association Guidelines for CPR and ECC. Dallas, TX:

American Heart Association; 2010. (167)

January CT et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation.

Circulation. 2014;130:e199–e267 (11).

Le Heuzey et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of

dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc

Electrophysiol. 2010;21:597. (75)

Mentzelopoulos SD et al. Vasopressin, steroids, and epinephrine and neurologically favorable survival after inhospital cardiac arrest: a randomized clinical trial. JAMA. 2013;310:270. (176)

Morillo CA et al. Radiofrequency ablation vs. antiarrhythmic drugs as first line treatment of paroxysmal atrial

fibrillation (RAAFT-2). A randomized trial. JAMA. 2014;311:692. (90)

Pederson CT et al. HER/HRS/APHRS expert consensus on ventricular arrhythmias. Heart Rhythm. 2014;11:e166.

(103)

Key Website

Blaufuss Medical Multimedia Laboratories ECG Tutorial. http://www.blaufuss.org.

COMPLETE REFERENCES CHAPTER 15 CARDIAC

ARRHYTHMIAS

Anon. Arrhythmias and conduction disorders (Chapter 213). In: Porter RS, Kaplan JL, eds. The Merck Manual of

Diagnosis & Therapy. 19th ed. Whitehouse Station, NJ: Merck & Co, Inc.; 2011:(E-book).

Sampson KJ, Kass RS. Antiarrhythmic drugs. In: Brunton LL, ed. Goodman & Gilman’s: The Pharmacologic

Basis of Therapeutics. New York, NY: McGraw Hill; 2011:815–848.

Menezes AR et al. Atrial fibrillation in the 21st Century: a current understanding of risk factors and primary

prevention strategies. Mayo Clin Proc. 2013;88:394–409.

Schnabel RB et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a communitybased cohort study. Lancet. 2009;373:739.

Wang TJ et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471.

Albers GW et al. Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med. 1991;115:727.

Falk RH et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded

trial. Ann Intern Med. 1987;106:503.

January CT et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of

the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the

Heart Rhythm Society. Circulation. 2014;130:e199–e267.

Rawles JM et al. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of

digoxin. Br Heart J. 1990;63:225.

Roberts SA et al. Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol.

1993;72:567.

Beasley R et al. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation.

Br Med J (Clin Res Ed). 1985;290:9.

Farshi R et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a

crossover open-labelstudy of five drug regimens. J Am Coll Cardiol. 1999;33:304.

Woodland C et al. The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell

monolayers. J Pharmacol Exp Ther. 1997;283:39.

Freitag D et al. Digoxin-quinidine and digoxin-amiodarone interactions: frequency of occurrence and monitoring in

Australian repatriation hospitals. J Clin Pharm Ther. 1995;20:179.

Weiner P et al. Clinical course of acute atrial fibrillation treated with rapid digitalization. Am Heart J.

1983;105:223.

Yancy CW et al. 2013 ACCF/AHA Guideline for the management of heart failure: executive summary.

Circulation. 2013;128:1810–1852.

White CM. Catecholamines and their blockade in congestive heart failure. Am J Health Syst Pharm. 1998;55:676.

Hariman RJ et al. Reversal of the cardiovascular effects of verapamil by calcium and sodium: differences

between electrophysiologic and hemodynamic responses. Circulation. 1979;59:797.

Lang J et al. Effect of gradual rise in plasma calcium concentration on the impairment of atrioventricular nodal

conduction due to verapamil. J Cardiovasc Pharmacol. 1986;8:6.

Salerno DM et al. Intravenous verapamil for treatment of multifocal atrial tachycardia with and without calcium

pretreatment. Ann Intern Med. 1987;107:623.

Pauli-Magnus C et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of Pglycoprotein. J Pharmacol Exp Ther. 2000;293:376.

Falk RH, Leavitt JI. Digoxin for atrial fibrillation: a drug whose time has gone? Ann Intern Med. 1991;114:573.

Zarowitz BJ, Gheorghiade M. Optimal heart rate control for patients with chronic atrial fibrillation: are

pharmacologic choices truly changing? Am Heart J. 1992;123:1401.

Rawles JM. What is meant by a “controlled” ventricular rate in atrial fibrillation? Br Heart J. 1990;63:157.

Van Gelder IC et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med.

2010;362:1363.

Wann LS et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation

(updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart

Association Task Force on Practice Guidelines. Heart Rhythm. 2011;8:157.

Wyse DG et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N EnglJ Med.

2002;347:1825.

Van Gelder IC et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial

fibrillation. N EnglJ Med. 2002;347:1834.

Gronefeld GC et al. Impact of rate versus rhythm control on quality of life in patients with persistent atrial

fibrillation. Results from a prospective randomized study. Eur Heart J. 2003;24:1430.

Opolski G et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation. The results

of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFÉ) Study. Chest. 2004;126:476.

Carlsson J et al. Randomized trial of rate-control versus rhythm-control inpersistent atrial fibrillation: the Strategies

of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690.

Roy D et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med.

2008;358:2667.

Keefe DL et al. Supraventricular tachyarrhythmias: their evaluation and therapy. Am Heart J. 1986;111:1150.

Morris JJ et al. Electrical conversion of atrial fibrillation: immediate and long-term results and selection of patients.

Ann Intern Med. 1966;65:216.

Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical

conversion of atrial fibrillation. Am J Cardiol. 1969;23:208.

Klein AL et al. Role of transesophageal echocardiography- guided cardioversion of patients with atrial fibrillation.

J Am Coll Cardiol. 2001;37:691.

de Divitiis M et al. Right atrial appendage thrombosis in atrial fibrillation: its frequency and its clinical predictors. J

Am Coll Cardiol. 1999;34:1867.

Falk RH, Podrid PJ. Electrical cardioversion of atrial fibrillation. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation:

Mechanisms and Management. New York, NY: Raven Press; 1992:181.

Kowey PR et al. Acute treatment of atrial fibrillation. Am J Cardiol. 1998;81(5A):16C.

Dunn AB et al. Efficacy and cost-analysis of ibutilide. Ann Pharmacother. 2000;34:1233.

Stambler BS et al. Efficacy and safety of repeated doses of ibutilide for rapid conversion of atrial flutter or

fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. 1996;94:1613.

Ellenbogen KA et al. Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J Cardiol.

1996;78(8A):42.

Naccarelli GV et al. Electrophysiology and pharmacology of ibutilide. Am J Cardiol. 1996;78(8A):12.

Kowey PR et al. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J

Cardiol. 1996;78(8A):46.

Boriani G et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying

heart disease. A randomized, controlled trial. Ann Intern Med. 1997;126:621.

Azpitarte J et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation.

Results of a randomized, double-blind, controlled study. Eur Heart J. 1997;18:1649.

Botto GL et al. Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is inhospital admission absolutely necessary? Pacing Clin Electrophysiol. 1996;19(11 Pt 2):1939.

Capucci A et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus

rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol. 1992;70:69.

Goy JJ et al. Restoration of sinus rhythm with flecainide in patients with atrial fibrillation. Am J Cardiol.

1988;62:38D.

Oral H et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N EnglJ Med.

1999;340:1849.

Hammill SC et al. Propafenone for atrial fibrillation. Am J Cardiol. 1988; 61:473.

Porterfield JG, Porterfield LM. Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J

Cardiol. 1989;63:114.

Pritchett EL et al. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A

randomized, placebo-controlled, crossover trial inpatients tolerating oral therapy. Ann Intern Med. 1991;114:539.

Pietersen AH, Hellemann H. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter.

Danish-Norwegian Flecainide Multicenter Study Group. Am J Cardiol. 1991;67:713.

Anderson JL et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially

tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with

transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation. 1989;80:1557.

Bolognesi R. The pharmacologic treatment of atrial fibrillation. Cardiovasc Drugs Ther. 1991;5:617.

Lafuente-Lafuente C et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.

Cochrane Database Syst Rev. 2007;(4):CD005049.

Chimienti M et al. Safety of long-term flecainide and propafenone in the management of patients with

symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study

Investigators. Am J Cardiol. 1996;77:60A.

Aliot E, Denjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients

with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am J Cardiol.

1996;77:66A.

Singh BN. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility. J

Cardiovasc Electrophysiol. 1999;10:283.

Kalus JS, Mauro VF. Dofetilide: a class III-specific antiarrhythmic agent. Ann Pharmacother. 2000;34:44.

Laughlin JC, Kowey PR. Dronedarone: a new treatment for atrial fibrillation. J Cardiovasc Electrophysiol.

2008;19:1220.

Benditt DG et al. Maintenance of sinus rhythm with oral D,L-sotalol therapy in patients with symptomatic atrial

fibrillation and/or atrial flutter. D,L-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1999;84:270.

Lee SH et al. Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic

paroxysmal atrial fibrillation. Am J Cardiol. 1997;79:905.

Roy D et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation

Investigators. N EnglJ Med. 2000;342:913.

Gosselink AT et al. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation

or flutter. JAMA. 1992;267:3289.

Greenbaum RA et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The

EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) Study

[abstract]. Circulation. 1998;98(Suppl):I–633.

Singh S et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with

chronic atrial fibrillation or atrial flutter. The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide

(SAFIRE-D) Study. Circulation. 2000;102:2385.

Torp-Pedersen C et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish

Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N EnglJ Med. 1999;341:857.

Køber L et al. Effect of dofetilide in patients with recent myocardial infarction and left ventricular dysfunction: a

randomised trial. Lancet. 2000;356:2052.

Song JC, White CM. Dofetilide (Tikosyn). Conn Med. 2000;64:601.

Singh BN et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med.

100.

2007;357:987.

Hohnloser SH et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med.

2009;360:668.

Køber L et al. Increased mortality after dronedarone therapy for severe heart failure [published correction

appears in N EnglJ Med. 2010;363:1384]. N EnglJ Med. 2008;358:2678.

Connolly SJ et al. Dronedarone in high risk permanent atrial fibrillation. N EnglJ Med. 2011;365:2268–2276.

Le Heuzey JY et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and

safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J

Cardiovasc Electrophysiol. 2010;21:597.

Betapace AF [product information]. Wayne, NJ: Berlex Laboratories; 2010.

Brass LM et al. Warfarin use among patients with atrial fibrillation. Stroke. 1997;28:2382.

Petersen P et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic

complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1:175.

[No authors listed]. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial

fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990;

323:1505.

[No authors listed]. Stroke Prevention in Atrial Fibrillation Investigators Study. Final results. Circulation.

1991;84:527.

[No authors listed]. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke

Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687.

Patel MR et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N EnglJ Med. 2011;365:883–891.

Granger CB et al. Apixaban versus warfarin in patients with atrial fibrillation. N EnglJ Med. 2011;365:981–992.

Giugliano RP et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–

2104.

Talati R, White CM. Dabigitran: a new orally available anticoagulant for prevention of strokes and thrombosis in

patients with atrial fibrillation. Formulary. 2011;46:44.

Connolly SJ et al. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N

EnglJ Med. 2010;363:1877]. N EnglJ Med. 2009;361:1139.

Stangier J et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran

etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259–268.

Kalus JS. Pharmacologic interventions for reversing the effects of oral anticoagulants. Am J Health Syst Pharm.

2013;70(Suppl 1):S12–S21.

Eikelboom JW et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med.

2013;369:1206–1214.

Morillo CA et al. Radiofrequency ablation vs. antiarrhythmic drugs as first line treatment of paroxysmal atrial

fibrillation (RAAFT-2). A randomized trial. JAMA. 2014;311:692–699.

Zipes DP. Specific arrhythmias: diagnosis and treatment. In: Braunwald E, ed. Braunwald’s Heart Disease: A

Textbook of Cardiovascular Medicine. Vol 1. 5th ed. Philadelphia, PA: WB Saunders; 1997:640.

Sager PT, Bhandari AK. Narrow complex tachycardias. Differential diagnosis and management. Cardiol Clin.

1991;9:619.

Faulds D et al. Adenosine. An evaluation of its use in cardiac diagnostic procedures, and in the treatment of

paroxysmalsupraventricular tachycardia. Drugs. 1991;41:596.

Garratt C et al. Comparison of adenosine and verapamil for termination of paroxysmal junctional tachycardia. Am

J Cardiol. 1989;64:1310.

 

140

Liver toxicity can range from an asymptomatic elevation of transaminases (2–4

times normal) to fulminant hepatitis. The mean latent period between the start of

amiodarone therapy and evidence of liver injury is 10 months (onset can be as short

as 3–4 days), but with rapid IV loading of amiodarone, a Reye’s-like fulminant

hepatitis can occur as early as 1 day after starting therapy, most likely caused by the

IV vehicle polysorbate-80. The precise mechanism of amiodarone-induced

hepatotoxicity has not been fully elucidated. However, higher doses and prolonged

drug use appear to place patients at higher risk of experiencing hepatotoxic effects of

amiodarone. Thus liver enzymes should be monitored at baseline, 1, 3, 6 months, and

semiannually afterward.

140,141 The most common GI complaints are nausea, anorexia,

and constipation, which occur in 25% of patients receiving amiodarone.

140

Both hypothyroidism and hyperthyroidism have been reported, although

hypothyroidism is more common. The thyroid complications are a consequence of

amiodarone’s large iodine content and its ability to block the peripheral conversion

of thyroxine (T4

) to triiodothyronine (T3

). In addition, amiodarone and its metabolite,

desethylamiodarone, appear to be directly cytotoxic to the thyroid gland.

142

Recent reports have indicated that photosensitive eruptions occur in 7% of

amiodarone recipients.

143 Classical presentations of amiodarone photosensitivity

involve a burning and tingling sensation in sun-exposed skin with accompanying

erythema. Approximately 1% to 2% of patients receiving amiodarone for long-term

use develop blue-gray pigmentation on sun-exposed skin. Resolution of amiodaroneassociated photo-induced pigmentation may take up to 2 years, with gradual fading of

skin discoloration.

143

In recent years, amiodarone-associated optic neuropathy has

been highlighted in multiple case reports. A review of amiodarone-associated optic

neuropathy (January 1993–May 2011) revealed a total of 214 cases from the FDA’s

Adverse Event Reporting System, 59 published cases, and 23 cases from clinical

trials.

144 On average, patients received amiodarone for 9 months (range 1–84 months)

before experiencing vision loss. In 20% of cases, patients progressed to legal

blindness in at least one eye. Other bothersome side effects are corneal deposits

(usually asymptomatic), exacerbation of heart failure, and central nervous system

effects that include ataxia, tremor, dizziness, and peripheral neuropathy. Other than

eye examination and pulmonary function tests, which should be repeated when the

patient is symptomatic, other tests should be repeated every 6 months (thyroid and

liver function) or annually (chest x-rays) for routine monitoring.

140,144 Amiodarone

also blocks multiple cytochrome P-450 enzyme systems and P-glycoprotein pumps,

resulting in clinically significant drug interactions.

p. 326

p. 327

Torsades de Pointes

PROARRHYTHMIC EFFECTS OF ANTIARRHYTHMIC DRUGS AND

CLINICAL PRESENTATION

CASE 15-8

QUESTION 1: L.G. is a 69-year-old woman who is taking sotalol 80 mg twice daily for a previous episode of

SuVT. L.G. was admitted to the hospital 3 days ago for altered mental status. She is also taking oral citalopram

40 mg every morning for major depressive disorder. At baseline, her QTc interval was 400 ms, and her CrCl

was 50 mL/minute. Other laboratory values are as follows:

Sodium, 139 mmol/L

Chloride, 108 mmol/L

Potassium, 4.0 mmol/L

CO2

, 22 mmol/L

Blood urea nitrogen (BUN), 32 mg/dL

Serum creatinine, 1.5 mg/dL

Random glucose, 102 mg/dL

Calcium, 8.5 mg/dL

Albumin, 2.9 g/dL

Phosphorous, 3.3 mg/dL

Today, her ECG reveals a QTc

interval of 502 ms and TdP, with a ventricular rate of 110 beats/minute.

What is QTc interval prolongation? Why does QTc interval prolongation indicate an increased risk of TdP?

Could an antiarrhythmic agent such as sotalol cause this arrhythmia? How does CrCl affect this?

The QT interval denotes ventricular depolarization (the QRS complex in the

cardiac cycle) and repolarization (from the end of the QRS complex to the end of the

T wave). Certain ion channels in phases 2 and 3 of the action potential are vital in

determining the QT interval (Fig. 15-1). An abnormal increase in ventricular

repolarization increases the risk of TdP. TdP is defined as a rapid polymorphic VT

preceded by QTc interval prolongation. TdP can degenerate into VF and as such can

be life threatening (Fig. 15-13).

145

Because there is tremendous variability in the QT interval resulting from changes

in heart rate, the QT is frequently corrected for heart rate (QTc interval). Several

correction formulas for the QT interval exist and give similar results at most heart

rates. The most common correction formula uses QT and R-R intervals measured in

seconds as follows: (QTc = QT/[R-R

0.5

]). However, overcorrection of the QT

interval may occur in persons with elevated heart rates (>85 beats/minute).

146,147 The

Fridericia correction (QTc = QT/[R-R

1/3

]) represents an alternative correction

method for patients with heart rates exceeding 85 beats/minute.

The ACC and AHA recently addressed the issue of the prevention of TdP in

hospital settings. They stated that each 10-ms increase in QTc confers an additional

5% to 7% TdP risk in patients with congenital long QT syndrome (LQTS).

147 The

International Conference on Harmonization stated that prolongation of QTc

interval

by more than 30 ms and in excess of 60 ms should be classified as a potential

adverse effect and a definite adverse effect, respectively.

148

Class Ia and class III antiarrhythmic agents have been shown to induce TdP in

numerous literature reports.

149 Of note, class Ia antiarrhythmic agents do not exhibit

dose-dependent association with TdP, whereas the incidence of TdP does appear to

be dose-related with class III antiarrhythmic agents. QT prolongation associated with

the use of class Ia antiarrhythmic agents is likely the result of blockade of outward

potassium channels, but it is offset by concomitant blockade of inward sodium

channels at increased drug concentrations.

150 TdP induced by class III antiarrhythmic

agents arises from prolonged repolarization and cardiac refractoriness. All class III

antiarrhythmic agents have been implicated in cases of TdP. A recent review of the

US FDA Adverse Event Reporting System (AERS) database showed the following

number of TdP cases that occurred during a 2-year time period: dronedarone (37),

amiodarone (29), dofetilide (12), and sotalol (4).

150

Incidence rates could not be

calculated because true denominators were not available and all events were selfreported. However, given the considerably larger prescriptive volume of

amiodarone, this agent appears to have a relatively low propensity for inducing TdP.

Class Ic antiarrhythmic agents do not exert significant effects on repolarization,

and therefore have rarely been shown to induce TdP. To date, eight cases of

flecainide-induced TdP have been published, along with one report of propafenoneassociated TdP.

151–153

Sotalol is known to cause QTc interval prolongation in a dose-dependent manner.

Total daily doses of 160, 320, 480, and >640 mg gave patients a steady-state QTc

interval of 467, 473, 483, and 512 milliseconds, and the incidence of TdP was 0.5%,

1.6%, 4.4%, and 5.8%, respectively.

154

It is likely that L.G.’s reduced renal function put her at high risk for sotalol

accumulation and accentuated QTc interval prolongation. In patients with a CrCl

greater than 60 mL/minute, the sotalol dose of 80 mg twice daily is appropriate, but

in patients like L.G. with a CrCl less than 40 to 60 mL/minute, the manufacturerrecommended dose should be 80 mg daily or 40 mg twice daily owing to sotalol’s

predominant renal clearance.

Figure 15-13 Torsades de pointes.

p. 327

p. 328

CASE 15-8, QUESTION 2: What transient conditions or other disorders can increase the risk of TdP in

patients on class Ia or III antiarrhythmic agents?

Hypokalemia, hypomagnesemia, hypocalcemia (rare cases of TdP), concurrent use

of more than one QT-prolonging drug, advanced age, female sex, heart disease (heart

failure or myocardial infarction), treatment with diuretics, impaired hepatic drug

metabolism, and bradycardia are important risk factors for TdP in hospitalized

patients.

147 Hypokalemia may prolong QT interval by modifying the function of the

inwardly rectifying potassium channel, resulting in heterogeneity and dispersion of

repolarization. Prolonged ventricular cycle length can assume the form of complete

AV block, sinus bradycardia, or a rhythm in which long cycles may progress to

arrhythmogenic EAD.

Congenital LQTS occurs in 1 in 2,500 individuals, and is a channelopathy

associated with mutations identified in genes encoding voltage-gated sodium and

potassium channels.

147 Since 1995, approximately 1,000 individual LQTS-causing

mutations have been detected in 12 distinct LQTS-susceptibility genes. The LQTSsusceptibility genes KCNQ1 (encoded IKs α-subunit), KCNH2 (encoded IKr αsubunit), and SCN5A (encoded Nav1.5 α-subunit) account for nearly 75% of all

congenital LQTS cases.

Because L.G. did not have a family history of hereditary LQTS but was being

treated with sotalol (an agent known to be associated with TdP) in renal dysfunction,

it can be assumed that sotalol therapy was responsible for her arrhythmia.

CASE 15-8, QUESTION 3: Which nonantiarrhythmic agents cause TdP? What is the mechanism of TdP

initiation in this situation?

PROARRHYTHMIC EFFECTS OF NONANTIARRHYTHMIC AGENTS

Nonantiarrhythmic agents can also exhibit potassium-channel inhibitory properties

and can prolong the QTc interval. Most of these drugs, including arsenic trioxide,

macrolide antibiotics, fluoroquinolones, azole antifungals, methadone,

antidepressants, organophosphorus compounds, and antipsychotics, cause QTc

interval prolongation by inhibiting the inwardly rectifying potassium ion channel, just

like quinidine and sotalol.

155 Moreover, toxic concentrations of nonantiarrhythmic

drugs can induce TdP as a result of large doses, impaired kidney or liver function, or

other drug therapy that interferes with metabolism of nonantiarrhythmic drugs.

On August 24, 2011, the US FDA sent out an alert to health care providers and

patients on new dosing recommendations for citalopram due to concerns of QTc

interval prolongation and TdP when using this agent at higher doses.

156 Key

recommendations included: (1) prescribing citalopram at a dose of ≤20 mg/day for

patients older than 60 years of age (also, in patients <60 years with hepatic

impairment or taking cimetidine); and (2) prescribing citalopram at a dose of ≤40

mg/day for younger patients. Hasnain and associates recently conducted a

comprehensive review of published literature on QTc

interval prolongation and/or

TdP risk associated with antidepressants and second-generation antipsychotics

(SGAPs).

157 The authors identified the highest number (16) of case reports

implicating citalopram, relative to other antidepressants, including fluoxetine (9),

escitalopram (6), venlafaxine (5), and sertraline (2). Case report material revealed

quetiapine as the SGAP with the largest number of QTc

interval prolongation and/or

TdP cases (16), followed by ziprasidone (13), risperidone (13), amisulpride,

olanzapine (6), and clozapine (5). The authors of the review noted that patients had at

least one additional risk factor for QTc

interval prolongation in 92% of the reports.

In addition, they acknowledged that the information yielded by case reports did not

allow for comparison between drugs and generalization to clinical practice.

During the past two decades, multiple case reports of methadone-induced TdP

have been published. Guidelines recommend QT interval monitoring, but some

experts have questioned the necessity of screening patients.

158 Kao et al.

158

reviewed

the FDA Adverse Event Reporting System (FAERS) database for QTc

interval

prolongation or TdP events linked with methadone compared to other agents,

including antiarrhythmic drugs and other opioids. Between 2000 and 2011, the three

most commonly implicated drugs included dofetilide (359 cases), methadone (211),

and sotalol (119). The authors acknowledged limitations of their analysis (voluntary

and selective reporting to FAERS, along with the inability to determine incidence

rates), but suggested that a REMS specific to methadone may be warranted, in order

to lower the risk of TdP. The recent emergence of methadone-associated TdP could

be attributable to escalating doses used in recent years, given the preponderance of

published cases of patients receiving very high doses of this agent.

159

Currently, the utility of published cardiac risk data on anti-infective agents is

limited, owing to underreporting, failure to completely eliminate contributory

confounding variables (cardiac disease, electrolyte abnormalities, use of other QTprolonging drugs), and the retrospective nature of some postmarketing studies.

148

However, the propensity of antimicrobial agents to induce QT prolongation appears

to be especially marked with macrolide antibiotics.

160 All of the commercially

available antifungal agents have been shown to induce TdP and QTc prolongation,

with a larger number of cases attributed to fluconazole, followed by voriconazole.

160

Among the marketed quinolones in the United States, ciprofloxacin appears to

display the lowest potential for causing TdP.

161

A list of nonantiarrhythmic agents implicated in causing QTc interval prolongation

and known pharmacokinetic drug interaction increasing the blood concentrations of

these drugs is given in Table 15-6.

Because L.G. was taking citalopram in combination with sotalol, it is likely that

QTc-prolonging effects resulting from concomitant use contributed to the

development of TdP.

TREATMENT

CASE 15-8, QUESTION 4: How should TdP be treated? What treatments should be considered for L.G.?

If the patient is significantly hemodynamically compromised (frequently associated

with a ventricular rate >150 beats/minute and unconsciousness) while in TdP,

electrical cardioversion is the therapy of choice and should be given immediately.

Stepwise increasing shocks of 100 to 200, 300, and 360 J (monophasic energy) can

be tried if earlier shocks are unsuccessful.

Magnesium

In a hemodynamically stable patient, magnesium is frequently considered the drug of

choice to restore normal sinus rhythm. It benefits patients whether they have

hypomagnesemia or normal serum magnesium levels. However, magnesium is not

effective for patients with polymorphic VT without TdP and with normal QT

intervals. Before administering magnesium, potassium levels should be supplemented

to the high normal range of 4.5 to 5.0 mmol/L.

155 A common magnesium regimen is 2

g given for 60 seconds through the IV route, followed by an infusion of 2 to 4

mg/minute.

155 The exact mechanism of action for magnesium in TdP is not known, but

it reduces the occurrence of triggered activity such as EAD. In addition, magnesium

blocks L-type calcium channels in the membrane, and may stabilize the membrane

gradient through activation of the sodium-potassium ATPase.

161

p. 328

p. 329

Table 15-6

Nonantiarrhythmic Agents with Known Torsades de Pointes Risk

a

Drug Class Agent

Drugs That Increase Blood Concentrations of These

QTc Interval–Prolonging Drugs

Anesthetic, general Propofol, sevoflurane

Antibiotics:

macrolides

Azithromycin,

clarithromycin,

erythromycin (lactobionate

and base)

Antibiotics:

fluoroquinolones

Ciprofloxacin,

levofloxacin, moxifloxacin

Antibiotics: other Pentamidine isethionate

Anti-cancer Arsenic trioxide,

vandetanib

Antidepressants Citalopram, Escitalopram CYP3A4 or 2C19 inhibitors

Antiemetics Chlorpromazine,

droperidol, ondansetron

CYP3A4 (primary for ondansetron), 1A2 (primary for

chlorpromazine), or 2D6 inhibitors

Antifungals Fluconazole

Antimalarials Chloroquine, halofantrine Cimetidine (chloroquine), CYP3A4 inhibitors (halofantrine)

Antipsychotics Haloperidol, pimozide,

thioridazine

CYP2D6 (thioridazine) or 3A4 (pimozide) inhibitors

Cholinesterase

inhibitors

Donepezil CYP3A4 or 2D6 inhibitors

Narcotics Methadone CYP3A4, 2B6, and 2C19 inhibitors

Phosphodiesterase 3

inhibitor

Anagrelide, cilostazol CYP1A2 (anagrelide), 3A4 (primary for cilostazol), or 2C19

inhibitors

aAn up-to-date list can be found at http://www.crediblemeds.org/everyone/

Other Treatment Options for TdP

Numerous other strategies have been utilized for patients who fail to respond

adequately to standard therapeutic approaches, including calcium-channel blockers,

αblockers, potassium-channel openers, lidocaine, and mexiletine.

162 However, the

evidence supporting these alternative agents is not compelling enough to classify

them as first-line options for abolishing TdP.

Cardio acceleration with isoproterenol (1–4 mcg/minute) or cardiac pacing has

also been shown to be beneficial.

163–165 As described previously, the ability of

sotalol, quinidine, and N-acetylprocainamide to prolong the APD is diminished at

faster heart rates (reverse use dependence).

166 The more the inwardly rectifying

potassium channels are activated, the less susceptible the channels are to inhibition

by potassium-channel blocking drugs.

Transvenous pacing has been shown to be of some use in abolishing refractory

TdP.

163 Before adjusting the ventricular rate to suppress ectopic ventricular beats, it

is essential to ensure proper catheter placement and cardiac capture. In general,

ventricular rates of 90 to 110 beats/minute can usually eliminate ventricular ectopy,

but some patients may require rates as high as 140 beats/minute. Once control of TdP

has been attained, the pacing rate can be gradually decreased to the lowest paced rate

that suppresses further ectopy and dysrhythmia.

Because L.G. is hemodynamically stable, a bolus injection of 2 g of magnesium

should be administered over 1 minute, followed by an infusion administered at a rate

of 2 to 4 mg/minute. In addition, she should receive potassium supplementation

(infusion) to achieve a potassium level of 4.5 to 5.0 mmol/L. If the arrhythmia recurs,

cardiac pacing should be used.

CARDIOPULMONARY ARREST

Cardiopulmonary Resuscitation

Cardiac arrest from VF, pulseless VT, pulseless electrical activity (PEA), and

asystole are life-threatening emergencies. Table 15-7

167–173

reviews commonly used

drugs for these indications, and Figure 15-14 highlights key features of the

management of pulseless arrest in the 2010 AHA Guidelines (2015 update to be

released in October 2015). This section will review important aspects of therapy and

will give clinical pearls, but the reader should also review the national consensus

source document for these disorders, which includes more detail than can be given

here.

167

Treatment

CASE 15-9

QUESTION 1: M.N., a 52-year-old man, is visiting his wife, who is hospitalized for pneumonia. His past

medical history is significant for hypertension and type 2 diabetes mellitus. He goes into the bathroom and 2

minutes later his wife hears a dull thud. She calls out for her husband, but he does not respond. After an

additional 2 minutes, health care workers open the bathroom door and find M.N. unresponsive and pulseless.

CPR is initiated and a code blue is called. The ECG shows VF (Fig. 15-12), and there is no BP. In addition to

CPR, what initial therapy is available?

Determining the underlying rhythm disturbance is important because it directs

health care workers to follow the Advanced Cardiac Life Support (ACLS) algorithm

for pulseless VT or VF (Fig. 15-14). This algorithm calls for electrical defibrillation

first, but other clinicians should work to establish IV access in case defibrillation

fails.

167

EXTERNAL DEFIBRILLATION

Although commercially available manual defibrillators provide monophasic or

biphasic waveform shocks, the biphasic defibrillator has become the preferred

device owing to its high first-shock efficacy.

167 Most commercially available

biphasic defibrillators display the device-specific energy dose range that should be

used. However, if a health care provider operating a manual biphasic defibrillator is

uncertain of the effective energy dose to terminate VF, using the maximal shock

energy setting available is preferred. For second and subsequent shocks delivered by

manual biphasic defibrillators, the same or higher energies should be used. For first

and subsequent shocks, a shock of 360 J should be delivered if a monophasic

defibrillator is used to terminate VF.

p. 329

p. 330

Table 15-7

Commonly Used Drugs in Cardiac Arrest

Drug Formulation Dosage/Administration Rationale/Indications Comments

Amiodarone 50 mg/mL

Vials: 3, 9, 18 mL

300 mg diluted in 20–30

mL D5W or NS;

additional 150 mg (diluted

solution) can be given for

recurrent or refractory

VT or VF.

Exhibits antiadrenergic

properties and blocks

sodium, potassium, and

calcium channels. Firstline antiarrhythmic for

pulseless VT and VF.

Excipients

(polysorbate 80

and benzyl

alcohol) can

induce

hypotension.

Failing to dilute

can induce

phlebitis.

Epinephrine 0.1 mg/mL

(1:10,000) or 1

mg/mL (1:1,000)

10 mL of a 1:10,000

solution of epinephrine (1

mg; dilute 1:1,000 solution

in 0.9% sodium chloride)

every 3–5 minutes.

Increases coronary

sinus perfusion

pressure through α1

stimulation.

Indicated in pulseless

VT, VF, asystole, and

PEA.

If administered

through peripheral

catheter, need to

flush the line to

get drug into the

central

compartment.

Vasopressin 20 units/mL

Vials: 0.5, 1, 10

mL

40-unit dose can be used

to replace first or second

dose of epinephrine

Increases coronary

sinus perfusion

pressure through

vasopressin receptor

stimulation.

Vasopressin is an

acceptable

alternative to

epinephrine, may

work better if time

Indicated in pulseless

VT, VF, asystole, and

PEA.

from cardiac

arrest to ACLS is

delayed.

ACLS, Advanced Cardiac Life Support; D5W, 5% dextrose in water; NS, normal saline; PEA, pulseless electrical

activity; VF, ventricular fibrillation; VT, ventricular tachycardia.

CASE 15-9, QUESTION 2: The initial shock fails to cause a return of spontaneous circulation in M.N. An

IV catheter is established in a peripheral arm vein. The algorithm now calls for epinephrine or vasopressin, but

which one should be used?

EPINEPHRINE AND VASOPRESSIN

Although epinephrine stimulates β1

-, β2

-, and α1

-adrenergic receptors, it is the α1

-

adrenoceptor effects that are most closely associated with efficacy in VF or pulseless

VT.

167 Applying α1

-adrenoceptor stimulation increases systemic vascular resistance

(via vasoconstriction), which elevates coronary perfusion pressure. This increase in

coronary perfusion pressure is most likely the key to enhancing the return of

spontaneous circulation after subsequent electrical defibrillation. Epinephrine may

convert fine VF to a coarse variety that may be more amenable to defibrillation.

The recommended dose of epinephrine is 1 mg (10 mL of a 1:10,000 dilution;

refer to Table 15-7) given by IV push. The dosage can be repeated at 3- to 5-minute

intervals during resuscitation. If the drug is given IV through a peripheral catheter,

which in this case includes a peripherally inserted central catheter, then a 20-mL

flush with normal saline is recommended to ensure delivery into the central

compartment. Only chest compressions cause blood circulation in VF or pulseless

VT, so movement of drugs from the periphery to the heart (where the benefit will

occur) is severely impaired.

Vasopressin is an exogenously administered antidiuretic hormone. In

supraphysiologic doses, vasopressin stimulates V1 receptors and causes peripheral

vasoconstriction. Vasopressin use during CPR causes intense vasoconstriction to the

skin, skeletal muscle, intestine, and fat, with much less constriction of coronary

vascular beds. Cerebral and renal vasodilation occurs as well.

Figure 15-14 Cardiac arrest treatment algorithm. CPR, cardiopulmonary resuscitation; DNR, do not resuscitate;

IO, intraosseous; IV, intravenous; PEA, pulseless electrical activity; ROSC, restoration of spontaneous circulation;

VF, ventricular fibrillation; VT, ventricular tachycardia.

p. 330

p. 331

The results of a prospective, randomized, controlled, multicenter study (n = 1,186)

that enrolled out-of-hospital cardiac arrest patients who presented with VF, PEA, or

asystole showed that administration of vasopressin as adjunctive therapy resulted in

similar survival to hospital admission rates (primary outcome measure) compared

with adjunctive epinephrine therapy.

168

In this study, patients were randomly assigned

to receive two ampules of 40 international units of vasopressin or two ampules of 1

mg of epinephrine. The second dose of vasopressor was injected if spontaneous

restoration of circulation did not occur within 3 minutes after the first injection of the

drug. If the absence of spontaneous circulation persisted, the physician administering

CPR had the option of injecting epinephrine. The reported survival rates were

similar between the two treatment groups for both patients with PEA and those with

VF.

An in-hospital study of 200 cardiac arrest patients (initial rhythm: 16%–20% VF,

3% VT, 41%–54% PEA, 27%–34% asystole) showed no difference in 1-hour or

hospital discharge survival for vasopressin 40 units versus epinephrine 1 mg.

169

Similarly, a meta-analysis of five randomized trials showed no survival advantage of

vasopressin treatment versus epinephrine treatment at the time of hospital discharge

or 24 hours after treatment.

170

Since the publication of the 2010 ACLS guideline, some study investigators have

focused on assessing long-term outcomes in out-of-hospital cardiac arrest

patients.

174,175 Hagihara and associates

174 showed that out-of-hospital cardiac arrest

patients who received epinephrine prior to hospital arrival had lower rates of 1-

month survival and 1-month survival with favorable neurologic function, compared

to patients who did not receive epinephrine (p < 0.001). Similarly, Goto et al.